Patient outcomes
| Pt . | Diagnosis . | Time with detectable T cells in PB . | AUC (CD19.CAR signal vs days of first infusion) . | Tumor response . | Number of cells infused (number of infusions) . |
|---|---|---|---|---|---|
| 1 | B-ALL/Ph+ | 12 wk | 223.11 | CR × 3 mo | 3.15 × 107 (2 infusions) |
| 2 | B-CLL/Richter’s | 1 wk | 97.38 | PR × 8 wk | 3.4 × 107 (2 infusions) |
| 3 | B-CLL/17p deletion | 2 wk | 136.395 | SD × 15+ months | 3.3 × 107 (3 infusions) |
| 4 | Pre–B-ALL | 12 wk | 247.45 | PD | 1.9 × 107 (2 infusions) |
| 5 | B-CLL/Richter’s | 8 wk | 348.215 | PD | 1 × 108 (1 infusion) |
| 6 | B-CLL/17p deletion | 4 wk | 71.82 | PD | 1.13 × 108 (2 infusions) |
| 7 | Pre–B-ALL/Ph+ | 12 wk* | 223.826 | CCR × 8 mo* | 9.7 × 107 (1 infusion) |
| 8 | B-ALL | 8 wk* | 946.19 | CCR × 2 mo* | 5.8 × 107 (1 infusion) |
| Pt . | Diagnosis . | Time with detectable T cells in PB . | AUC (CD19.CAR signal vs days of first infusion) . | Tumor response . | Number of cells infused (number of infusions) . |
|---|---|---|---|---|---|
| 1 | B-ALL/Ph+ | 12 wk | 223.11 | CR × 3 mo | 3.15 × 107 (2 infusions) |
| 2 | B-CLL/Richter’s | 1 wk | 97.38 | PR × 8 wk | 3.4 × 107 (2 infusions) |
| 3 | B-CLL/17p deletion | 2 wk | 136.395 | SD × 15+ months | 3.3 × 107 (3 infusions) |
| 4 | Pre–B-ALL | 12 wk | 247.45 | PD | 1.9 × 107 (2 infusions) |
| 5 | B-CLL/Richter’s | 8 wk | 348.215 | PD | 1 × 108 (1 infusion) |
| 6 | B-CLL/17p deletion | 4 wk | 71.82 | PD | 1.13 × 108 (2 infusions) |
| 7 | Pre–B-ALL/Ph+ | 12 wk* | 223.826 | CCR × 8 mo* | 9.7 × 107 (1 infusion) |
| 8 | B-ALL | 8 wk* | 946.19 | CCR × 2 mo* | 5.8 × 107 (1 infusion) |
Follow-up still ongoing.